These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 21410668)

  • 21. Ex vivo nail infection as an effective preclinical method for screening of new topical antifungals.
    Quatrin PM; Kaminski TFA; Berlitz SJ; Guerreiro ICK; Canto RFS; Fuentefria AM
    J Mycol Med; 2020 Jun; 30(2):100938. PubMed ID: 32111505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential of Naftifine Application for Transungual Delivery.
    Šveikauskaitė I; Briedis V
    Molecules; 2020 Jul; 25(13):. PubMed ID: 32635240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro transungual permeation of ciclopirox from a hydroxypropyl chitosan-based, water-soluble nail lacquer.
    Monti D; Saccomani L; Chetoni P; Burgalassi S; Saettone MF; Mailland F
    Drug Dev Ind Pharm; 2005 Jan; 31(1):11-7. PubMed ID: 15704853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An investigation into keratinolytic enzymes to enhance ungual drug delivery.
    Mohorcic M; Torkar A; Friedrich J; Kristl J; Murdan S
    Int J Pharm; 2007 Mar; 332(1-2):196-201. PubMed ID: 17097244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the antifungal efficacy of terbinafine hydrochloride and ciclopirox olamine containing formulations against the dermatophyte Trichophyton rubrum in an infected nail plate model.
    Täuber A; Müller-Goymann CC
    Mol Pharm; 2014 Jul; 11(7):1991-6. PubMed ID: 24490976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Controlled nail delivery of a novel lipophilic antifungal agent using various modern drug carrier systems as well as in vitro and ex vivo model systems.
    Naumann S; Meyer JP; Kiesow A; Mrestani Y; Wohlrab J; Neubert RH
    J Control Release; 2014 Apr; 180():60-70. PubMed ID: 24560884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Distribution of Luliconazole in Nail Plate by In Vitro Permeation and Efficacy by Zone of Inhibition Test after Treatment of Luliconazole Nail Solution].
    Shimamura T; Miyamae A; Arai M; Minemura A; Nozawa A; Kubota N
    Med Mycol J; 2016; 57(1):J19-25. PubMed ID: 26936348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of topical antifungal products in an in vitro onychomycosis model.
    Sleven R; Lanckacker E; Delputte P; Maes L; Cos P
    Mycoses; 2016 May; 59(5):327-30. PubMed ID: 26857689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ciclopirox nail lacquer: a brush with onychomycosis.
    Gupta AK
    Cutis; 2001 Aug; 68(2 Suppl):13-6. PubMed ID: 11665723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ciclopirox delivery into the human nail plate.
    Hui X; Wester RC; Barbadillo S; Lee C; Patel B; Wortzmman M; Gans EH; Maibach HI
    J Pharm Sci; 2004 Oct; 93(10):2545-8. PubMed ID: 15349963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes.
    Seebacher C; Nietsch KH; Ulbricht HM
    Cutis; 2001 Aug; 68(2 Suppl):17-22. PubMed ID: 11665724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative clinical evaluation of efficacy and safety of a formulation containing ciclopirox 8% in the form of a therapeutic nail lacquer in two different posologies for the treatment of onychomycosis of the toes.
    Schalka S; Nunes S; Gomes Neto A
    An Bras Dermatol; 2012; 87(1):19-25. PubMed ID: 22481647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis.
    Avner S; Nir N; Henri T
    J Dermatolog Treat; 2005; 16(5-6):327-30. PubMed ID: 16428154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ciclopirox vs amorolfine: in vitro penetration into and permeation through human healthy nails of commercial nail lacquers.
    Monti D; Tampucci S; Chetoni P; Burgalassi S; Mailland F
    J Drugs Dermatol; 2014 Feb; 13(2):143-7. PubMed ID: 24509963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the Ability of a Novel Miconazole Formulation To Penetrate Nail by Using Three
    Christensen L; Turner R; Weaver S; Caserta F; Long L; Ghannoum M; Brown M
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers.
    Sidou F; Soto P
    Int J Tissue React; 2004; 26(1-2):17-24. PubMed ID: 15573688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transungual delivery of ketoconazole using novel lacquer formulation.
    Hafeez F; Hui X; Chiang A; Hornby S; Maibach H
    Int J Pharm; 2013 Nov; 456(2):357-61. PubMed ID: 24029171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Permeation studies of novel terbinafine formulations containing hydrophobins through human nails in vitro.
    Vejnovic I; Huonder C; Betz G
    Int J Pharm; 2010 Sep; 397(1-2):67-76. PubMed ID: 20620203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of topical therapeutics for management of onychomycosis and other nail disorders: a pharmaceutical perspective.
    Elsayed MM
    J Control Release; 2015 Feb; 199():132-44. PubMed ID: 25481439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Onychomycosis does not always require systemic treatment for cure: a trial using topical therapy.
    Friedlander SF; Chan YC; Chan YH; Eichenfield LF
    Pediatr Dermatol; 2013; 30(3):316-22. PubMed ID: 23278851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.